Eurofins CDMO vs Pfizer CentreOne: CDMO Comparison
How does Eurofins CDMO compare to Pfizer CentreOne for Biologics manufacturing?
Side-by-side comparison of Eurofins CDMO and Pfizer CentreOne on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Pfizer CentreOne holds 14 active EMA GMP certificates; Eurofins CDMO does not appear in EudraGMDP.
- Pfizer CentreOne maintains 3 MHRA / UK GMP certificates; Eurofins CDMO does not.
- Pfizer CentreOne appears as a manufacturing partner on more matched clinical programs (368 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Eurofins CDMO and Pfizer CentreOne qualify as Biologics manufacturers; Pfizer CentreOne carries the higher composite Signal Score for Biologics programs in this comparison.
What to evaluate for Biologics programs
Both Eurofins CDMO and Pfizer CentreOne qualify as Biologics CDMOs. When choosing between them for Biologics programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Scale & bioreactor fit
Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.
Cell line & process development
Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.
Regulatory track record
Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.
Drug substance to drug product
Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.
Frequently asked: Eurofins CDMO vs Pfizer CentreOne
How does Eurofins CDMO compare to Pfizer CentreOne for Biologics manufacturing?
On CDMO Signal's composite Signal Score, Eurofins CDMO is 82/100 and Pfizer CentreOne is 92/100; Eurofins CDMO has 5 FDA inspections on record vs 4 for Pfizer CentreOne; European coverage is 0 active EMA+MHRA certificates for Eurofins CDMO vs 17 for Pfizer CentreOne. Both are tracked in the CDMO Signal directory as Biologics CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Eurofins CDMO or Pfizer CentreOne?
Both Eurofins CDMO and Pfizer CentreOne maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Eurofins CDMO has 5 FDA inspections on record; Pfizer CentreOne has 4.
How do Eurofins CDMO and Pfizer CentreOne compare on European GMP coverage?
Eurofins CDMO holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Pfizer CentreOne holds 14 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Eurofins CDMO or Pfizer CentreOne?
Eurofins CDMO is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Pfizer CentreOne is matched to 368. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Biologics manufacturing — Eurofins CDMO or Pfizer CentreOne?
Both Eurofins CDMO and Pfizer CentreOne are tagged as Biologics CDMOs in our directory, so both are credible options for Biologics programs. The most important differentiator for Biologics selection is typically scale & bioreactor fit: Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →